| scholarly article | Q13442814 |
| P2093 | author name string | Mina Massaro-Giordano | |
| Vatinee Y Bunya | |||
| Matthew Henderson | |||
| Erin C O'Neil | |||
| P2860 | cites work | Topical administration of lacritin is a novel therapy for aqueous-deficient dry eye disease | Q24563932 |
| Prospective evaluation of intense pulsed light and meibomian gland expression efficacy on relieving signs and symptoms of dry eye disease due to meibomian gland dysfunction | Q33650494 | ||
| Effect of thermal pulsation treatment on tear film parameters in dry eye disease patients | Q33686685 | ||
| The economic burden of dry eye disease in the United States: a decision tree analysis | Q34147677 | ||
| A new system, the LipiFlow, for the treatment of meibomian gland dysfunction. | Q34245032 | ||
| A single LipiFlow® Thermal Pulsation System treatment improves meibomian gland function and reduces dry eye symptoms for 9 months. | Q34253558 | ||
| Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years | Q34443357 | ||
| Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction; a 3-year retrospective study | Q34458485 | ||
| Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. | Q34462573 | ||
| Intense pulsed light therapy for the treatment of evaporative dry eye disease | Q34479938 | ||
| Combination Therapy of Intense Pulsed Light Therapy and Meibomian Gland Expression (IPL/MGX) Can Improve Dry Eye Symptoms and Meibomian Gland Function in Patients With Refractory Dry Eye: A Retrospective Analysis | Q34509790 | ||
| Reduced Levels of Tear Lacritin Are Associated With Corneal Neuropathy in Patients With the Ocular Component of Sjögren's Syndrome | Q34542159 | ||
| The validity and practicality of sun-reactive skin types I through VI. | Q34687744 | ||
| Human meibum lipid conformation and thermodynamic changes with meibomian-gland dysfunction | Q35027689 | ||
| Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease | Q35592019 | ||
| Comparison of Two Questionnaires for Dry Eye Symptom Assessment: The Ocular Surface Disease Index and the Symptom Assessment in Dry Eye | Q35798154 | ||
| PERSIST: Physician's Evaluation of Restasis(®) Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review | Q36444344 | ||
| Accelerated Restoration of Ocular Surface Health in Dry Eye Disease by Self-Retained Cryopreserved Amniotic Membrane | Q36445561 | ||
| Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study | Q36877000 | ||
| A nonrandomized, open-label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye disease | Q36887538 | ||
| The sustained effect (12 months) of a single-dose vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye. | Q37143007 | ||
| Prevalence, burden, and pharmacoeconomics of dry eye disease. | Q37152821 | ||
| Prosthetic replacement of the ocular surface ecosystem: impact at 5 years | Q37235832 | ||
| Transcription, translation, and function of lubricin, a boundary lubricant, at the ocular surface | Q37460389 | ||
| The Limitation of Applying Heat to the External Lid Surface: A Case of Recalcitrant Meibomian Gland Dysfunction | Q37634890 | ||
| Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. | Q38171801 | ||
| Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies. | Q38400516 | ||
| Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial | Q38414042 | ||
| Current and Emerging Therapeutic Strategies for the Treatment of Meibomian Gland Dysfunction (MGD). | Q38541101 | ||
| Primary Mechanisms of Thymosin β4 Repair Activity in Dry Eye Disorders and Other Tissue Injuries | Q38560551 | ||
| Lifitegrast for the treatment of dry eye disease in adults | Q38608475 | ||
| Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older | Q38680274 | ||
| Dynamic Intraductal Meibomian Probing: A Modified Approach to the Treatment of Obstructive Meibomian Gland Dysfunction | Q39145216 | ||
| Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature | Q39151688 | ||
| Efficacy of Intraductal Meibomian Gland Probing on Tear Function in Patients With Obstructive Meibomian Gland Dysfunction | Q39175481 | ||
| Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. | Q39203016 | ||
| The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind crossover study | Q39211271 | ||
| Intraductal meibomian gland probing relieves symptoms of obstructive meibomian gland dysfunction | Q39283231 | ||
| Outcomes of intense pulsed light therapy for treatment of evaporative dry eye disease. | Q39493112 | ||
| Use of Prosthetic Replacement of the Ocular Surface Ecosystem Scleral Lenses in Patients with Ocular Chronic Graft-versus-Host Disease | Q40668788 | ||
| Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group | Q40765221 | ||
| Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group | Q41730611 | ||
| Optisol corneal storage medium | Q42608242 | ||
| PROSE Treatment for Ocular Chronic Graft-Versus-Host Disease as a Clinical Network Expands. | Q43607997 | ||
| Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury | Q43957139 | ||
| Patient ocular conditions and clinical outcomes using a PROSE scleral device | Q44035708 | ||
| Evaluation of topical cyclosporine for the treatment of dry eye disease | Q44443222 | ||
| The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study | Q45284543 | ||
| Prosthetic Replacement of the Ocular Surface Ecosystem Treatment of Ocular Surface Disease After Skull Base Tumor Resection. | Q46267868 | ||
| Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3). | Q46401944 | ||
| Prosthetic replacement of the ocular surface ecosystem as treatment for ocular surface disease in patients with a history of Stevens-Johnson syndrome/toxic epidermal necrolysis | Q46830241 | ||
| Six-month effects of a thermodynamic treatment for MGD and implications of meibomian gland atrophy | Q46842302 | ||
| Treatment of persistent corneal epithelial defect with overnight wear of a prosthetic device for the ocular surface. | Q46989348 | ||
| Treatment of Dry Eye Disease with Autologous Platelet-Rich Plasma: A Prospective, Interventional, Non-Randomized Study. | Q47155411 | ||
| Growth of meibomian gland tissue after intraductal meibomian gland probing in patients with obstructive meibomian gland dysfunction | Q47287812 | ||
| Dry eye syndrome: developments and lifitegrast in perspective | Q47639135 | ||
| Long-term use of autologous serum 50% eye drops for the treatment of dry eye disease. | Q47802474 | ||
| Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs. | Q47852975 | ||
| Comparison of a single-dose vectored thermal pulsation procedure with a 3-month course of daily oral doxycycline for moderate-to-severe meibomian gland dysfunction. | Q49337437 | ||
| EyePrintPRO therapeutic scleral contact lens: indications and outcomes. | Q50093567 | ||
| A Two-Week, Randomized, Double-masked Study to Evaluate Safety and Efficacy of Lubricin (150 μg/mL) Eye Drops Versus Sodium Hyaluronate (HA) 0.18% Eye Drops (Vismed®) in Patients with Moderate Dry Eye Disease. | Q51167595 | ||
| Effectiveness of Intraductal Meibomian Gland Probing for Obstructive Meibomian Gland Dysfunction. | Q51404581 | ||
| Clinical benefits of the Boston Ocular Surface Prosthesis. | Q51801804 | ||
| Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye. | Q52608828 | ||
| Improvement of chronic corneal opacity in ocular surface disease with prosthetic replacement of the ocular surface ecosystem (PROSE) treatment. | Q52649408 | ||
| Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products. | Q52661549 | ||
| Randomized Controlled Crossover Trial Comparing the Impact of Sham or Intranasal Tear Neurostimulation on Conjunctival Goblet Cell Degranulation. | Q52889830 | ||
| Analysis of Meibum Before and After Intraductal Meibomian Gland Probing in Eyes With Obstructive Meibomian Gland Dysfunction. | Q53401335 | ||
| Long-Term (3 Year) Effects of a Single Thermal Pulsation System Treatment on Meibomian Gland Function and Dry Eye Symptoms. | Q53403135 | ||
| Gas-permeable scleral contact lens therapy in ocular surface disease. | Q53511908 | ||
| Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. | Q53620228 | ||
| A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. | Q54222666 | ||
| Treatment outcomes in the DRy Eye Amniotic Membrane (DREAM) study. | Q55009490 | ||
| A novel system, TearCare®, for the treatment of the signs and symptoms of dry eye disease. | Q55280295 | ||
| Amniotic membrane extract and eye drops: a review of literature and clinical application. | Q55412517 | ||
| RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model. | Q55618002 | ||
| A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease | Q57484944 | ||
| Dry eye: prevalence, utilization, and economic implications | Q75260269 | ||
| Low-cost protocol for the production of autologous serum eye drops by blood collection and processing centres for the treatment of ocular surface diseases | Q83522538 | ||
| Work productivity loss in patients with dry eye disease: an online survey | Q83645366 | ||
| A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis | Q83830053 | ||
| Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta 4 | Q84198739 | ||
| Intraductal meibomian gland probing in the management of ocular rosacea | Q84632006 | ||
| [Intraductal meibomian gland probing for the treatment of blepharitis] | Q87361219 | ||
| Evaluation of an automated thermodynamic treatment (LipiFlow®) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial | Q87666057 | ||
| Intranasal Tear Neurostimulation: An Emerging Concept in the Treatment of Dry Eye | Q89466701 | ||
| Effectiveness of Intraductal Meibomian Gland Probing in Addition to the Conventional Treatment in Patients with Obstructive Meibomian Gland Dysfunction | Q91577290 | ||
| Neurostimulation in dry eye disease-past, present, and future | Q93007713 | ||
| Characterization of tear production in subjects with dry eye disease during intranasal tear neurostimulation: Results from two pivotal clinical trials | Q93344260 | ||
| P433 | issue | 3 | |
| P921 | main subject | eye disease | Q3041498 |
| P304 | page(s) | 166-178 | |
| P577 | publication date | 2019-05-01 | |
| P1433 | published in | Current Opinion in Ophthalmology | Q15757956 |
| P1476 | title | Advances in dry eye disease treatment | |
| P478 | volume | 30 |
Search more.